Liraglutide Outperforms Other Weight-Loss Treatments at Regenerating Insulin-Producing Cells in Diabetic Rats | Research

The takeaway

While liraglutide, naltrexone/bupropion, and caloric restriction all improved metabolic health in diabetic rats, only liraglutide and caloric restriction actually regenerated insulin-producing beta cells — with liraglutide uniquely lowering beta-arrestin-1, a key signaling protein.

Beta-cell regeneration with liraglutide
Liraglutide and caloric restriction both increased Ki67 (cell division marker) in pancreatic beta cells, while naltrexone/bupropion — despite producing greater weight loss — did not

What the researchers found

In 50 male diabetic rats across five groups, all three interventions significantly improved body weight, BMI, blood glucose, insulin, lipid profiles, and atherogenic indices compared to untreated diabetic controls.

Key differentiators:

- **Beta-cell regeneration**: Liraglutide and caloric restriction significantly increased anti-insulin antibodies and Ki67 (a cell proliferation marker) in the pancreas, indicating beta-cell regeneration. Naltrexone/bupropion (NTX+BUP) showed no significant regenerative effect.

- **Beta-arrestin-1**: Liraglutide significantly decreased beta-arrestin-1 levels compared to both NTX+BUP and caloric restriction — a unique molecular signature.

- **Weight loss**: NTX+BUP and caloric restriction produced greater weight loss than liraglutide, yet liraglutide was superior for beta-cell outcomes.

Why it matters

Most diabetes treatments manage symptoms but don't fix the underlying problem — progressive beta-cell loss. This study shows liraglutide can actually regenerate beta cells, potentially reversing the disease process rather than just controlling it. The finding that weight loss alone (from NTX+BUP) doesn't regenerate beta cells while liraglutide does suggests the GLP-1 pathway has specific regenerative properties beyond its metabolic effects.

How the study worked

Fifty male albino rats were randomized into five groups: normal control, diabetic control, diabetic + 50% caloric restriction, diabetic + NTX+BUP (4 mg/45 mg/kg/day oral), and diabetic + liraglutide (0.3 mg/kg/day subcutaneous). Outcomes included body weight, BMI, serum glucose, insulin, lipid profile, atherogenic indices, beta-arrestin-1 levels, pancreatic histopathology, and immunohistochemical staining for insulin and Ki67 (proliferation marker).

What this study cannot tell us

This is a preclinical rat study, and beta-cell regeneration dynamics may differ significantly in humans. The sample size (10 per group) is modest. The study used a chemically induced diabetes model, which may not perfectly replicate the gradual onset of human type 2 diabetes. Only male rats were studied. The duration of treatment and long-term sustainability of beta-cell regeneration were not assessed.

How to read the evidence

This is a preclinical study in a rat diabetes model with a clear experimental design (5 groups, n=50 total). While the comparative approach is informative, the results require validation in human studies before clinical application.

When this study was published

Published in 2024, this study is very current and addresses ongoing debates about whether GLP-1 agonists have disease-modifying (not just symptom-managing) effects in type 2 diabetes.

The bigger picture

The question of whether GLP-1 agonists can truly regenerate beta cells — not just protect existing ones — is one of the most important in diabetes research. If confirmed in humans, it would mean drugs like liraglutide and semaglutide could potentially reverse type 2 diabetes rather than merely managing it. The beta-arrestin-1 finding also opens a new molecular pathway that could be targeted for next-generation therapies.

Questions still open

Does liraglutide's beta-cell regenerative effect translate to humans, and could long-term GLP-1 agonist use reverse type 2 diabetes?
What is the specific role of beta-arrestin-1 reduction in mediating beta-cell regeneration — is it a cause or a consequence?
Would combining liraglutide with caloric restriction produce additive beta-cell regeneration effects?

Common questions

Can GLP-1 drugs like liraglutide actually reverse diabetes by growing new insulin-producing cells?

This rat study suggests yes — liraglutide increased markers of beta-cell regeneration (new cell growth) in the pancreas. If this translates to humans, it could mean GLP-1 drugs don't just manage blood sugar but actually repair the underlying damage of type 2 diabetes. However, human confirmation is still needed.

If Contrave (naltrexone/bupropion) causes more weight loss, why was liraglutide better for the pancreas?

This is one of the study's key insights: weight loss alone isn't enough to regenerate beta cells. Liraglutide appears to have direct effects on the pancreas through the GLP-1 receptor pathway — including reducing a protein called beta-arrestin-1 — that go beyond its weight-loss effects. The GLP-1 receptor is actually present on beta cells themselves.

Read the original research

Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.

Journal of molecular histology, 56(1), 50

View on PubMed ↗Publisher’s paper ↗

Citation

Merzeban, Dina H; El Amin Ali, Amani M; Hammad, Reem O; Elmahdi, Mohamed H; Sofi, Marwa A; Mahmoud, Rania H; Metwally, Sayed M; El Ebiary, Ahmed M. (2024). Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.. Journal of molecular histology, 56(1), 50. https://doi.org/10.1007/s10735-024-10326-x